Ursodeoxycholate [60], novel mitochondrial transition pore inhibitor N-methyl-4-isoleucine cyclosporin [61], inhibitors of TRPM2 [62], kynurenic acid and its analog SZR-72 [63], CFTR corrector (VX-661) and potentiator (VX-770) [64], and fentanyl [65] improved the outcome of pancreatitis in different experimental models. This evidence concerns the gene CFTR and pancreatitis.